Search

Your search keyword '"Milliez, P."' showing total 1,234 results
Start Over Author "Milliez, P."
1,234 results on '"Milliez, P."'

7. Some essential skills and their combination in an architecture for a cognitive and interactive robot

Author

Devin, Sandra, Milliez, Grégoire, Fiore, Michelangelo, Clodic, Aurélie, and Alami, Rachid

Subjects
Computer Science - Robotics
Abstract

The topic of joint actions has been deeply studied in the context of Human-Human interaction in order to understand how humans cooperate. Creating autonomous robots that collaborate with humans is a complex problem, where it is relevant to apply what has been learned in the context of Human-Human interaction. The question is what skills to implement and how to integrate them in order to build a cognitive architecture, allowing a robot to collaborate efficiently and naturally with humans. In this paper, we first list a set of skills that we consider essential for Joint Action, then we analyze the problem from the robot's point of view and discuss how they can be instantiated in human-robot scenarios. Finally, we open the discussion on how to integrate such skills into a cognitive architecture for human-robot collaborative problem solving and task achievement., Comment: Presented at "2nd Workshop on Cognitive Architectures for Social Human-Robot Interaction 2016 (arXiv:1602.01868)"

Published
2016

14. Distinct Substrates of Idiopathic Ventricular Fibrillation Revealed by Arrhythmia Characteristics on Implantable Cardioverter-Defibrillator

Author

Haïssaguerre, Michel, Sellal, Jean-Marc, Benali, Karim, de Becker, Benjamin, Defaye, Pascal, Pascale, Patrizio, Martins, Raphael, Mabo, Philippe, Xhaet, Olivier, Extramiana, Fabrice, Surget, Elodie, Lavergne, Thomas, Marijon, Eloi, Adragao, Pedro, Carvalho, Maria Salomé, Milliez, Paul-Ursmar, Laredo, Mickael, Gandjbakhch, Estelle, Giustetto, Carla, Gaita, Fiorenzo, Tilz, Roland, Jesel-Morel, Laurence, Steinfurt, Johannes, Arentz, Thomas, Knecht, Sebastien, Duytschaever, Mattias, Roten, Laurent, Reichlin, Tobias, Fatemi, Marjaneh, Mansourati, Jacques, Kouakam, Claude, Bessière, Francis, Chevalier, Philippe, Tadros, Rafik, Macle, Laurent, Gallego, Francisco, Hadjis, Alexios, Sacher, Frederic, Pereira, Dylan, Hourdain, Jerome, Deharo, Jean-Claude, Eschalier, Romain, Massoulié, Grégoire, Maury, Philippe, Latcu, Decebal Gabriel, Anselme, Frederic, Duchateau, Josselin, Tixier, Romain, Nademanee, Koonlawee, Nogami, Akihiko, de Groot, Natasja, Vigmond, Edward, Bernus, Olivier, Strik, Marc, Bordachar, Pierre, Cathala, Aude, Bouteiller, Xavier, Dubois, Remi, and Ploux, Sylvain

Abstract

Idiopathic ventricular fibrillation (IVF) can be associated with undetected distinct conditions such as microstructural cardiomyopathic alterations (MiCM) or Purkinje (Purk) activities with structurally normal hearts.

Published
2024
Full Text
View/download PDF

30. Conduction system pacing in France in 2022: A snapshot survey from the Working Group of Pacing and Electrophysiology of the French Society of Cardiology.

Author

Ollitrault, Pierre, Chaumont, Corentin, Font, Jonaz, Amelot, Mathieu, Brejoux, Célia, Champ-Rigot, Laure, Ferchaud, Virginie, Garcia, Rodrigue, Gomes, Sophie, Lebon, Alain, Loiselet, Philippe, Martins, Raphaël, Metais, Denis, Pellissier, Arnaud, Defaye, Pascal, Milliez, Paul, and Anselme, Frédéric

Abstract

[Display omitted] • CSP is an innovative approach but evidence and guidelines are lacking. • CSP has been widely adopted in France. • Important variations were apparent for implantation techniques and success criteria. • Lack of training and clinical guidelines remain limitations for wider CSP adoption. Conduction system pacing (CSP) is an emerging and promising approach for physiological ventricular pacing. While data from randomized controlled trials are scarce, use of His-bundle pacing (HBP) and left bundle branch area pacing (LBBAP) has increased in France. To perform a national snapshot survey for cardiac electrophysiologists to evaluate adoption of CSP in France. An online survey, distributed to every senior cardiac electrophysiologist in France, was conducted in November 2022. A total of 120 electrophysiologists completed the survey. Eighty-three (69%) respondents reported experience in undertaking CSP procedures and 27 (23%) were planning to start performing CSP in the coming 2 years. The implantation techniques and criteria used for successful implantation differed significantly among operators. The most frequent indications for HBP and LBBAP were high-degree atrioventricular block with left ventricular ejection fraction (LVEF) < 40% (24 and 82%, respectively) or with LVEF ≥ 40% (27 and 74%, respectively), and after failure of a coronary sinus left ventricular lead (27 and 71%, respectively). The limitations respondents most frequently perceived when performing HBP were bad sensing/pacing parameters (45%), increased procedure duration (41%) and risk of lead dislodgement (30%). The most frequently perceived limitations to performing LBBAP were absence of guidelines or consensus (31%), lack of medical training (23%) and increased procedure duration (23%). Our national survey-based study supports wide adoption of CSP in France. CSP is currently used as a second-line approach for both antibradycardia and resynchronization indications, with important variations regarding implantation techniques and criteria for measuring success. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. Atrial fibrillation, cancer and anticancer drugs.

Author

Font, Jonaz, Milliez, Paul, Ouazar, Alexandre-Boudjema, Klok, Frederikus A., and Alexandre, Joachim

Abstract

[Display omitted] • Several anticancer drugs are associated with development of atrial fibrillation. • Ibrutinib is the drug most associated with AF, with a ≈ 4-fold increased risk. • AF incidence in active cancer is underestimated. • AF management in active cancer follows the ABC pathway, with adaptations. Active cancer is associated with an increased risk of atrial fibrillation (AF), which varies depending on the pre-existing substrate (particularly in older patients), the cancer type and stage, and the anticancer therapeutics being taken. To date, studies have not been able to identify the individual contribution of each factor. During anticancer drug therapy, AF may occur with a frequency of ≈ 15–20% according to several factors, including the patient's baseline cardiovascular toxicity risk and the AF-detection strategies used. Many anticancer drugs have been associated with AF or AF reporting, both in terms of incident and recurrent AF, but robust data are lacking. Only bruton tyrosine kinase inhibitor associated AF (mainly ibrutinib) has a high level of evidence, with a ≈ 3–4-fold higher risk of AF. AF in patients with active cancer is associated with a twofold higher risk of systemic thromboembolism or stroke, and the "TBIP" (Thromboembolic risk, Bleeding risk, drug–drug Interactions, Patient preferences) structured approach must be used to evaluate the need for anticoagulation therapy. AF in patients with active cancer is also associated with a sixfold higher risk of heart failure, and optimal symptom control must be targeted, usually with rate-control drugs (beta-blockers), but a rhythm-control strategy may be proposed in patients remaining symptomatic despite optimal rate-control. AF is generally manageable, with the continuation of anticancer drugs (including ibrutinib); interruption of cancer drugs must be avoided whenever possible and weighed against the risk of cancer progression. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Factors influencing LDL-c after acute coronary syndrome and effectiveness of intensive monitoring by teleconsultation: The TELEOBJECTIF cohort study.

Author

Cauvin, J., Roule, V., Legallois, D., Sabatier, R., Dejardin, O., Rebouh, I., Schwob, L., Heudel, T., Péron, C., Blanchart, K., Bignon, M., Lemaitre, F., Milliez, P., Beygui, F., and Lemaitre, A.

Abstract

Low-density lipoprotein cholesterol (LDL-c) plays a key role in the development and progression of atherosclerotic cardiovascular disease (ASCVD). Despite the availability of effective lipid-lowering treatments, patients who have experiencedan acute coronary syndrome (ACS) continue to face a high risk of recurrentcardiovascular events and mortality. Achieving the recommended LDL-c target of < 0.55 g/L in secondary cardiovascular prevention remains a significant challenge, with fewer than 30% of patients reaching this goal. To investigate the factors influencing LDL-c control after ACS and the effectiveness of intensive teleconsultation monitoring to control LDL-c, even in sub-groups where control is poorest. This bi-centric prospective cohort study conducted between December 2019 and December 2021 compared a group that received standard follow-up after an ACS with an interventional group that received regular follow-up by teleconsultation in addition of usual care to optimize lipid-lowering treatment. A subgroup analysis was carried out to examine the effect of teleconsultation in subpopulations known to be significantly associated with better or worse LDL-c control in the usual caregroup or described in the literature. Seven hundred and eighty-eight in the teleconsultation group. Baseline characteristics were similar between groups. In the usual care group, factors influencing lipid control included gender, diabetes, cardiology consultation, distance to the nearest cardiologist, social deprivation and initial LDL-c levels. Teleconsultation significantly improved LDL-c target attainment compared to usual care (74.7 vs. 26.6%, P < 0.001 with multivariate analysis OR 5.06 [4.21; 6.07]), particularly benefiting geographically and socially disadvantaged patients. Teleconsultation significantly improves lipid control in acute coronary syndrome patients compared to usual care. This universal intervention, particularly beneficial for geographically and socially disadvantaged patients, highlights the potential of telemedicine in enhancing cardiovascular management (Fig. 1). [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

33. Impact of teleconsultation follow-up to control LDL-c at one year after acute coronary syndrome: A prospective cohort study.

Author

Cauvin, J., Legallois, D., Roule, V., Sabatier, R., Albot, A., Schwob, L., Rebouh, I., Heudel, T., Blanchart, K., Lemaitre, F., Joubert, M., Bignon, M., Milliez, P., Beygui, F., and Lemaitre, A.

Abstract

High level of low-density lipoprotein (LDL-c) is one of the most important causal and independent risk factors for recurrent atheromatous cardiovascular events. Despite the availability of several treatments that can reduce LDL-c by up to 85%, less than 30% of patients achieve the LDL-c target < 0.55 g/dL, recommended by the European Society of Cardiology for secondary cardiovascular prevention. We hypothesized that teleconsultation monitoring would allow better control of LDL-c blood levels at one year in a population after acute coronary syndrome (ACS). This bi-centric prospective cohort study conducted between December 2019 and December 2021 compared a group that received standard follow-up after an ACS with an interventional group that received regular follow-up by teleconsultation in addition of usual care to optimize lipid-lowering treatment. One thousand six hundred and two patients met the inclusion criteria for our study (814 in the usual care group and 788 in the teleconsultation group). The proportion of patients with LDL-c < 0.55 g/L at one year was statistically significant in the teleconsultation group (74.7%) compared with the usual care group (26.6%) (P < 0.001) (Fig. 1). The average (standard deviation) absolute value of LDL-c at 1 year was 0.48 g/L (0.2) in the teleconsultation group and 0.75 g/L (0.32) in the usual care group (P < 0.001). In the multivariate analysis, receiving teleconsultation follow-up made it more likely to achieve the LDL-c target (4.88 [4,09; 5,85], P < 0.001). The use of lipid-lowering treatments, including statins, ezetimibe and PCSK9 inhibitors was much higher in the teleconsultation group (P < 0.001). There was a significant difference in overall survival (P = 0.016) and cardiovascular survival (P = 0.013) in favor of the teleconsultation group. Teleconsultation follow-up after ACS significantly improved lipid control and survival at one year. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

50. Poster presentation

Author

Duparc, F., Noyon, M., Ozeel, J., Gerometta, A., Michot, C., Tadjalli, M., Moslemy, H., Safaei, S., Heiman, A., Wish-Baratz, S., Melnikov, T., Smoliar, E., Hakan, A. Y., Yucel, F., Kachlík, D. K., Pešl, M. P., Báča, V. B., Stingl, J. S., Kachlík, K. D., Čech, Č. P., Báča, B. V., Mompeó, B., Marrero-Rodriguez, A., Zeybek, A., Sağlam, B., Çikler, E., Çetinel, Ş., Ercan, F., Şener, G., Kawawa, Y., Kohda, E., Tatsuya, T., Moroi, M., Kunimasa, T., Nagamoto, M., Terada, H., Labuschagne, B. C. J., van der Krieke, T. J., Hoogland, P. V., Muller, C. J. F., Lyners, R., Vorster, W., Matusz, P., Zaboi, D. E., Xu, S. C., Tu, L. L., Wang, Q., Zhang, M., Han, H., Tao, W., Jiao, Y., Pang, G., Aydin, M. E., Kopuz, C., Demir, M. T., Yildirim, M., Kale, A., Ince, Y., Khamanarong, K., Jeeravipoolvarn, P., Chaijaroonkhanarak, W., Gawgleun, W., Fujino, T., Uz, A., Apaydin, N., Bozkurt, M., Elhan, A., Sheibani, M. T., Adibmoradi, M., Jahovic, N., Alican, I., Erkanli, G., Arbak, S., Karakaş, S., Taşer, F., Güneş, H., Yildiz, Y., Yazici, Y., Aland, R. C., Kippers, V., Song, W. C., Park, S. H., Shin, C., Koh, K. S., Russo, G., Pomara, F., Veca, M., Cacciola, F., Martorana, U., Gravante, G., Tobenas-Dujardin, A. C., Laquerrière, A., Muller, J. M., Fréger, P., López-Serna, N., Álvarez-González, E., Torres-Gonzàlez, V., Laredo-López, G., Esparza-González, G. V., Álvarez-Cantú, R., Garza-González, C. E., Guzmán-López, S., Aldur, M. M., Çelik, H. H., Sürücü, S., Denk, C., Yang, H. J., Gil, Y. C., Kim, T. J., Lee, H. Y., Lee, W. J., Lee, H., Hu, K. S., Akita, K., Kim, H. J., Jung, H. S., Gurbuz, H., Balik, S., Wavreille, G., Chantelot, C., Demondion, X., Fontaine, C., Çavdar, S., Yalin, A., Saka, E., Özdoǧmuş, Ö., Çakmak, Ö., Elevli, L., Saǧlam, B., Coquerel-Beghin, D., Milliez, P. Y., Lemierre, G., Oktem, G., Vatansever, S., Ayla, S., Uysal, A., Aktas, S., Karabulut, B., Bilir, A., Uslu, S., Aktug, H., Yurtseven, M. E., Celik, H. H., Tatar, I., Surucu, S., Karaduman, A., Tunali, S., Neuhüttler, S., Kröll, A., Moriggl, B., Brenner, E., Loukas, M., Arora, S., Louis, Jr, R. G., Fogg, Q. A., Wagner, T., Tedman, R. A., Ching, H. Y., Eze, N., Bottrill, I. D., Blyth, P., Faull, R. L. M., Vuletic, J., Elizondo-Omaña, R. E., Rodríguez, M. A. García, López, S. Guzmán, de la Garza, O. Tijerina, Liu, Y. H., Zhang, K. L., Lu, D. H., Kwak, H. H., Park, H. D., Youn, K. H., Kang, H. J., Kang, H. C., Han, S. H., Ikiz, Z. A. Aktan, Ucerler, H., Uygur, M., Kutoglu, T., Dina, C., Iliescu, D., Şapte, E., Bordei, P., Lekšan, I., Marcikić, M., Radić, R., Nikolić, V., Kurbel, S., Selthofer, R., Báča, V., Doubková, A., Kachlík, D., Stingl, J., Džupa, V., Grill, R., Nam, Y. S., Paik, D. J., Shin, C. S., Kim, S. J., Kim, D. G., Jin, C. S., Kim, D. I., Lee, U. Y., Kwak, D. S., Lee, J. H., Han, C. H., Carpino, A., Rago, V., Romeo, F., Carani, C., Andò, S., Arican, R. Y., Coskun, N., Sarikcioglu, L., Sindel, M., Arican, Y. R., Altun, U., Ozsoy, U., Oguz, N., Yildirim, F. B., Nakajima, K., Duygulu, E., Aydin, H., Gurer, E. Inanc, Ozkan, O., Tuzuner, S., Özsoy, U., Çubukçu, S., Demirel, B. M., Akkin, S. M., Marur, T., Weiglein, A. H., Maghiar, T. T., Borza, C., Bumbu, A., Bumbu, G., Polle, G., Auquit-Auckbur, I., Dujardin, F., Biga, N., Olivier, E., Defives, T., Ghazali, S., Anastasi, G., Rizzo, G., Favaloro, A., Miliardi, D., Giacobbe, O., Santoro, G., Trimarchi, F., Cutroneo, G., Govsa, F., Bilge, O., Ozer, M. A., Erdogmus, S., Grizzi, F., Pelillo, F., Mori, M., Franceschini, B., Portinaro, N., Godlewski, G., Viala, M., Rouanet, J. P., Prat, D., Rahmé, Z. S., Prudhomme, M., Eken, E., Kwiatkowska, M., Liegmann, J., Chmielewski, R., Grimmond, J., Kwiatkowski, M., Schintler, M. V., Windisch, G., Wittgruber, G., Prandl, E. C., Prodinger, P., Anderhuber, F., Scharnagl, E., Gerbino, A., Buscemi, M., Leone, A., Mandracchia, R., Peri, G., Lipari, D., Farina-Lipari, E., Valentino, B., D’Arpa, S., Cordova, A., Bucchieri, F., Ribbene, A., David, S., Palma, A., Davies, D. E., Haitchi, H. M., Holgate, S. T., La Rocca, G., Anzalone, R., Campanella, C., Rappa, F., Bartolotta, T., Cappello, F., Bellafiore, M., Sivverini, G., Palumbo, D., Macaluso, F., Farina, F., Di Felice, V., Montalbano, A., Ardizzone, N., Marcianò, V., Zummo, G., Tanyeli, E., Üzel, M., Carini, F., Scardina, G. A., Varia, P., Valenza, V., Messina, P., Meiring, J. H., Schumann, C., Whitmore, I., Greyling, L. M., Hamel, O., Hamel, A., Robert, R., Garçon, M., Lagier, S., Blin, Y., Armstrong, O., Rogez, J. M., Le Borgne, J., Ifrim, C. Feng, Maghiar, A., Botea, M., Ifrim, M., Pop, O., Sandor, M., Behdadipour, Z., Saberi, M., Esfandiary, E., Gentile, C., Marconi, A., Livrea, M. A., Uzan, G., D’Alessio, P., Ridola, C. G., Grassi, N., Pantuso, G., Bottino, A., Cacace, E., Li Petri, S., Di Gaudio, F., Guercio, G., Latteri, M. A., Nobile, D., Cipolla, C., Caruso, G., Salvaggio, G., Lo Cascio, A., Fatta, G., Lagalla, R., Campisi, A., Verderame, F., Martegani, A., Cardinale, A. E., and Luedinghausen, M. V.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results